Jasper Therapeutics Appoints Jeet Mahal As CEO And Board Member; Thomas Wiggans Becomes Executive Chairperson

Jasper Therapeutics, Inc., a clinical-stage biotechnology company developing briquilimab, a novel antibody therapy targeting KIT (CD117) for mast cell–driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, has announced that its Board of Directors has appointed Jeet Mahal as President and Chief Executive Officer, as well as a member of the Board. His appointment becomes effective January 5, 2026. Mr. Mahal will succeed Ronald Martell, who has served as CEO since 2022. In addition, Thomas Wiggans, the current Chairperson of the Board, has been named Executive Chairperson.

Thomas Wiggans said the company is entering an important phase as it prepares to begin its registrational program for briquilimab in CSU. He noted that Jeet Mahal brings a strong track record in therapeutic development and extensive leadership experience in guiding biotech companies through the shift from early-stage research to global clinical trials. He also acknowledged Ronald Martell’s contributions, highlighting his leadership in redirecting the development of briquilimab toward mast cell–driven conditions and thanking him for his support during the transition. According to Wiggans, Jeet’s strategic insight and industry experience position him well to advance Jasper’s programs and create long-term value for both patients and shareholders.

Mr. Mahal joins the CEO role with more than three decades of experience in the life sciences sector. Over the past six years at Jasper, he has served in critical leadership positions including Chief Business and Financial Officer and, most recently, Chief Operating Officer. His earlier career includes senior business development, commercial, and operational roles at Portola Pharmaceuticals, Johnson & Johnson, and COR Therapeutics. He has contributed to the development and strategic advancement of several approved medicines, including Andexxa, Bevyxxa, and Xarelto.

Reflecting on his appointment, Mr. Mahal said he is honored to lead Jasper at a pivotal moment in the company’s evolution. He noted that briquilimab has shown promising and differentiated results in both CSU and CIndU, along with proof of concept in asthma. As the company transitions toward its Phase 2b study in CSU, his immediate priority will be to ensure the successful completion of ongoing trials while strengthening plans for briquilimab’s continued development.

Ronald Martell, who guided Jasper’s shift toward allergic and immunological mast cell–driven diseases and helped establish clinical proof of concept for briquilimab in CSU, CIndU, and allergic asthma, shared his appreciation for the team. He said it has been a privilege to lead the organization and expressed pride in the scientific and clinical progress made under his tenure. Martell also affirmed his commitment to supporting Jeet Mahal through the leadership transition and to advocating for the company’s future success.